JP2021503501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503501A5 JP2021503501A5 JP2020545072A JP2020545072A JP2021503501A5 JP 2021503501 A5 JP2021503501 A5 JP 2021503501A5 JP 2020545072 A JP2020545072 A JP 2020545072A JP 2020545072 A JP2020545072 A JP 2020545072A JP 2021503501 A5 JP2021503501 A5 JP 2021503501A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- halogen
- compound according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 93
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical group 0.000 claims description 33
- 150000002148 esters Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000003831 deregulation Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000006662 intracellular pathway Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- -1 cyclopentynyl Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000000034 method Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 0 C*(C)(C)c(cc1)cc(N(CC([N+]([O-])=O)=*)c(c2ccc3Cl)c3OC(*)=C)c1C2=O Chemical compound C*(C)(C)c(cc1)cc(N(CC([N+]([O-])=O)=*)c(c2ccc3Cl)c3OC(*)=C)c1C2=O 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588820P | 2017-11-20 | 2017-11-20 | |
| US62/588,820 | 2017-11-20 | ||
| US201862631530P | 2018-02-16 | 2018-02-16 | |
| US62/631,530 | 2018-02-16 | ||
| US201862723660P | 2018-08-28 | 2018-08-28 | |
| US62/723,660 | 2018-08-28 | ||
| PCT/US2018/062021 WO2019100061A1 (en) | 2017-11-20 | 2018-11-20 | Oxoacridinyl acetic acid derivatives and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503501A JP2021503501A (ja) | 2021-02-12 |
| JP2021503501A5 true JP2021503501A5 (enExample) | 2022-01-06 |
| JP7323539B2 JP7323539B2 (ja) | 2023-08-08 |
Family
ID=66540425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545072A Active JP7323539B2 (ja) | 2017-11-20 | 2018-11-20 | オキソアクリジニル酢酸誘導体および使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10745358B2 (enExample) |
| EP (1) | EP3713920A4 (enExample) |
| JP (1) | JP7323539B2 (enExample) |
| KR (1) | KR20200100081A (enExample) |
| CN (1) | CN111630036B (enExample) |
| AU (1) | AU2018368789B2 (enExample) |
| BR (1) | BR112020009592A2 (enExample) |
| CA (1) | CA3079262A1 (enExample) |
| IL (1) | IL274796A (enExample) |
| MX (1) | MX2020004902A (enExample) |
| PH (1) | PH12020550652A1 (enExample) |
| SG (1) | SG11202004442VA (enExample) |
| WO (1) | WO2019100061A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| JP2022533390A (ja) * | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| EP3983078B1 (en) * | 2019-06-12 | 2023-11-15 | Ryvu Therapeutics S.A. | Next-generation modulators of stimulator of interferon genes (sting) |
| CN112442033A (zh) * | 2019-08-28 | 2021-03-05 | 迈德欣国际有限公司 | Sting通路调节剂及其用途 |
| CN112624972A (zh) * | 2019-09-24 | 2021-04-09 | 中国人民解放军军事科学院军事医学研究院 | 吖啶酮类化合物及医药用途 |
| RU2730530C1 (ru) * | 2019-10-29 | 2020-08-24 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Новое химическое соединение L-лизина 9-оксоакридинил-10-ацетат, стимулирующее продукцию интерлейкина-24 и фактора некроза опухолей - бета |
| WO2021083383A1 (zh) * | 2019-11-02 | 2021-05-06 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN111039849B (zh) * | 2019-12-26 | 2021-07-06 | 阜阳欣奕华材料科技有限公司 | 一种含有咔唑环类化合物的制备方法 |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681360A (en) | 1971-04-09 | 1972-08-01 | Hoffmann La Roche | Antiviral substituted acridanones |
| JPH0867873A (ja) | 1994-08-29 | 1996-03-12 | Pioneer Electron Corp | 有機エレクトロルミネッセンス素子 |
| CA2213706A1 (en) | 1995-03-02 | 1996-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Novel quinuclidine derivative having tricyclic hetereo condensed ring |
| EP0857721A4 (en) | 1995-10-04 | 1999-07-28 | Eisai Co Ltd | ACRIDONE-BASED COMPOUNDS |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| RU2118532C1 (ru) * | 1996-04-10 | 1998-09-10 | Олег Викторович Травкин | Противоинфекционное, противовоспалительное и противоопухолевое лекарственное средство |
| JPH11100373A (ja) * | 1997-09-26 | 1999-04-13 | Eisai Co Ltd | 新規フェノチアジン誘導体及びその医薬 |
| RU2197248C2 (ru) * | 2001-03-20 | 2003-01-27 | Травкин Олег Викторович | Лекарственный препарат, обладающий иммуномоделирующим, иммунокоррегирующим, противопаразитарным, противосклеротическим, противовирусным, противобактериальным, противогрибковым, противовоспалительным и противоопухолевым действием, и способ его приготовления |
| GB0113434D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Quinacridone derivatives as labels for fluorescence detection of biological materials |
| GB0113435D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Acridone derivatives as labels for fluorescence detection of target materials |
| JP2006526137A (ja) | 2003-05-28 | 2006-11-16 | ジーイー・ヘルスケア・ユーケイ・リミテッド | 内部標準の存在下で色素を標識することによる閉じた膜構造上の細胞表面タンパク質の示差分析 |
| CN1937994A (zh) * | 2004-04-06 | 2007-03-28 | 宝洁公司 | 角蛋白染色化合物、包含它们的角蛋白染色组合物以及它们的应用 |
| JP2006004736A (ja) | 2004-06-17 | 2006-01-05 | Sumitomo Chemical Co Ltd | 光電変換素子及び光電変換素子用色素 |
| WO2008021745A2 (en) | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
| JP2008090130A (ja) * | 2006-10-04 | 2008-04-17 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料 |
| US20110039289A1 (en) | 2008-03-14 | 2011-02-17 | Pierre Graves | Fluorogenic peptides and their method of production |
| JP2009271403A (ja) | 2008-05-09 | 2009-11-19 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料および平版印刷版の製造方法 |
| JP5717959B2 (ja) | 2009-11-17 | 2015-05-13 | 株式会社Adeka | 芳香族スルホニウム塩化合物 |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
| JP6082474B2 (ja) | 2013-09-30 | 2017-02-15 | 富士フイルム株式会社 | 感光性樹脂組成物、硬化膜の製造方法、硬化膜、有機ｅｌ表示装置および液晶表示装置 |
| KR20160065858A (ko) * | 2013-10-21 | 2016-06-09 | 드렉셀유니버시티 | 만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용 |
| CN103709122B (zh) | 2013-11-29 | 2016-05-25 | 四川大学 | 用于治疗的抗肿瘤和抗真菌化合物 |
| WO2016179702A1 (en) * | 2015-05-11 | 2016-11-17 | Ranju Ralhan | Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers |
| US11938128B2 (en) | 2017-03-10 | 2024-03-26 | Albert Einstein College Of Medicine | Small molecule BAX inhibitors and uses thereof |
-
2018
- 2018-11-20 AU AU2018368789A patent/AU2018368789B2/en not_active Ceased
- 2018-11-20 CN CN201880086600.0A patent/CN111630036B/zh active Active
- 2018-11-20 CA CA3079262A patent/CA3079262A1/en active Pending
- 2018-11-20 KR KR1020207017927A patent/KR20200100081A/ko not_active Ceased
- 2018-11-20 JP JP2020545072A patent/JP7323539B2/ja active Active
- 2018-11-20 WO PCT/US2018/062021 patent/WO2019100061A1/en not_active Ceased
- 2018-11-20 US US16/195,997 patent/US10745358B2/en active Active
- 2018-11-20 BR BR112020009592-3A patent/BR112020009592A2/pt not_active IP Right Cessation
- 2018-11-20 SG SG11202004442VA patent/SG11202004442VA/en unknown
- 2018-11-20 EP EP18878928.3A patent/EP3713920A4/en active Pending
- 2018-11-20 MX MX2020004902A patent/MX2020004902A/es unknown
-
2020
- 2020-05-15 PH PH12020550652A patent/PH12020550652A1/en unknown
- 2020-05-20 IL IL274796A patent/IL274796A/en unknown
-
2022
- 2022-07-28 US US17/875,770 patent/US20230113570A1/en not_active Abandoned